Iu. S. Osipov

Iu. S. Osipov

Auto-generated profile, based on publicly available information

Iu. S. Osipov

VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2026 in Clinical oncohematology
Verified
Journal Article
Open access
TST. V. Shelekhova
T. V. Shelekhova
JKJ. Kumar
J. Kumar
SAS. J. Apte
S. J. Apte
IOIu. S. Osipov
Iu. S. Osipov
EME. N. Misyurina
E. N. Misyurina
DLD. O. Liaptseva
D. O. Liaptseva
AIM. To confirm the comparability of the biosimilar daratumumab BCD-264 (BIOCAD) with the reference drug Darzalex (Johnson & Johnson) in terms of efficacy and safety of the monotherapy for relapsed/refractory (r/r) multiple myeloma (MM). MATERIALS & METHODS. This paper is based on the double-blind prospective comparative randomized phase 3 clinical trial BCD-264-2/DARVIVA assessing the efficacy and safety of BCD-264 and Darzalex as monotherapy for r/r MM. Duration of the blind period was 24 weeks. The trial enrolled 252 r/r MM patients treated with proteasome inhibitors and immunomodulatory drugs. This paper documents the analysis of the data collected within the blind period when the therapy was administered to Group 1 and Group 2, whereby neither the investigators nor the patients knew which drug is being used in each of the groups. RESULTS. The primary end point of the study was overall response rate (ORR) in 24 weeks after therapy onset. In Group 1, ORR was 36.2 % and it was 32.0 % in Group 2; ORR ratio for Group 1/2 was 1.13 (95% confidence interval [95% CI] 0.80–1.60) and 0.88 (95% CI 0.63–1.24) for Group 2/1. This confirmed the hypothesis of BCD-264 being no less effective than Darzalex. Besides, an additional hypothesis of drug equivalence was proved true demonstrating also the comparability of the drugs across all secondary efficacy end points and safety parameters. The most common adverse events reported in both groups were leukopenia, neutropenia, lymphopenia, anemia, thrombocythemia, infusion-associated reactions, and pneumonia. CONCLUSION. Both drugs BCD-264 and Darzalex showed comparable efficacy and safety during the 24-week period in the BCD-264-2/DARVIVA trial as well as comparable immunogenicity and pharmacokinetic profile.

1 July 2026 in Clinical oncohematology
Verified
Journal Article
Open access
ATA. A. Tsynchenko
A. A. Tsynchenko
OPOlga Vladislavovna Pirogova
Olga Vladislavovna Pirogova
IOIu. S. Osipov
Iu. S. Osipov
OKO. V. Kudyasheva
O. V. Kudyasheva
YZYu. R. Zalyalov
Yu. R. Zalyalov
AKAlexander Kulagin
Alexander Kulagin
BACKGROUND. РOEMS syndrome is a rare multisystem syndrome associated with monoclonal proliferation of plasma cells or B-lymphocytes and based on cytokine-mediated pathogenetic mechanism. Despite the clear diagnostic criteria, timely verification of the diagnosis is challenging due to the extreme variability of clinical features. AIM. To study clinical and laboratory profile as well as diagnostic routes of patients with РOEMS syndrome. MATERIALS & METHODS. This retrospective observational study enrolled 40 patients with newly diagnosed РOEMS syndrome treated at two major centers for hematology in the period from 01.2016 to 09.2025. RESULTS. On the date of POEMS syndrome diagnosis, the median age of patients was 58 years (range 28–80 years), and median time from symptom manifestation to diagnosis was 23 months (range 1–146 months). On initial presentation at the Federal center, 30 % of patients were severely disabled and completely immobilized. All of them met two essential criteria: polyneuropathy and monoclonal gammopathy. In the vast majority of cases, polyneuropathy manifested itself in a sensory and motor form (87.5 %) with predominantly mixed axonal and demyelinating lesions (79.4 %). Paraprotein was identified in 97.5 % of patients, however in 30 % of them the pathologic clone of plasma cells was not detected by standard techniques. Other manifestations of POEMS syndrome include bone abnormalities (62.5 %), increased VEGF level (73 %), organomegaly (75 %), endocrinopathy (60 %), skin lesions (52.5 %), extravascular fluid overload (47.5 %), and thrombocytosis/polycythemia (45 %). Prior to diagnosis verification, on average, patients were examined by 3 (range 1–6) medical specialists, most often by a neurologist (62.5 %). At the diagnostic stage, chronic inflammatory demyelinating polyneuropathy (32.5 %) was widely and wrongly assumed. After examination by related specialists, 80 % of patients were referred to a hematologist. In 50 % of cases, lymphoproliferative diseases were identified, however, without verification of POEMS syndrome. In 20 % of patients, myeloproliferative neoplasia was wrongly diagnosed. CONCLUSION. For timely diagnosis of POEMS syndrome, medical specialists should raise awareness and alertness concerning its polymorphic clinical features and additionally strengthen interdisciplinary approaches.

22 May 2025 in Oncohematology
Verified
Journal Article
Open access
PDF file
YOYu. S. Osipov
Yu. S. Osipov
AAA. A. Antonov
A. A. Antonov
VIV. V. Ivanov
V. V. Ivanov
GSG. N. Salogub
G. N. Salogub
The article discusses the epidemiology and difficulties of diagnosing invasive aspergillosis in patients with acute myeloid leukemia, the role of pharmacokinetic and pharmacogenetic studies in choosing the optimal treatment regimen, and an attempt at pharmacoeconomic analysis to create an optimal treatment strategy for this complication.

1 April 2026 in Clinical oncohematology
Verified
Journal Article
Open access
LFLiudmila Fedorova
Liudmila Fedorova
NMN. B. Mikhailova
N. B. Mikhailova
KLKirill V. Lepik
Kirill V. Lepik
ACA. M. Chekalov
A. M. Chekalov
OSO. G. Smykova
O. G. Smykova
AKAlexander Kulagin
Alexander Kulagin
BACKGROUND. Clinical trials of glofitamab (Glofit) have demonstrated its high efficacy and tolerable toxicity profile in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients. However, the data on its use in a real-world setting remain sparse. AIM. To assess the efficacy and safety of Glofit in the combined cohort of R/R DLBCL patients in a real-world setting in the Russian Federation. MATERIALS & METHODS. This retrospective multi-center study enrolled 88 R/R DLBCL patients treated with Glofit under a compassionate use program from 2021 to 2024 in 22 Russian medical institutions. The median age of patients was 54 years (range 21–83 years), there were 42 (48 %) male patients. The main eligibility criteria were ≥ 3 prior therapy lines and exhaustion of available standard treatment methods. Glofit was administered as a monoregimen according to the schedule recommended in the package insert. RESULTS. With the follow-up median of 8.4 months (range 0.6–52 months), overall response was achieved in 46 (53 %) patients including 36 (42 %) patients with complete response (CR). The median overall survival (OS) was 13.1 months (95% confidence interval [95% CI] from 8.6 months to not reached), the 1-year OS was 55.7 % (95% CI 45.6–68.1 %). The median progression-free survival (PFS) was 4.2 months (95% CI 2.8–8.8 months), and the 1-year PFS was 33.5 % (95% CI 24.6–45.8 %). The median OS and PFS in patients with CR was not reached, whereas the 1-year PFS and OS were 73.7 % (95% CI 59.4–91.5 %) and 87.9 % (95% CI 77.4–99.9 %), respectively. Adverse events (AEs) were reported in 75 (85 %) patients, among them AEs of grade ≥ 3 in 35 (40 %) patients. Cytokine release syndrome was identified in 33 (38 %) patients, and “flare” syndrome was registered in 14 (16 %) patients. Infectious complications were observed in 45 (51 %) patients. Grade 5 AEs included only COVID-19 infection (n = 7; 8 %). Male gender, early relapse/refractoriness as well as 3-month administration of bendamustine prior to Glofit therapy were associated with the rate of achieving CR. PFS was lower in bendamustine recipients and also in cases with B-symptoms and massive tumor (bulky, > 7.5 cm). CONCLUSION. Glofit demonstrated high efficacy and tolerable toxicity profile in the treatment of R/R DLBCL patients. The results obtained in a real-world setting confirm the data from previously published clinical trials.

1 July 2026 in Clinical oncohematology
Verified
Journal Article
Open access
VMVladislav Vitalevich Markelov
Vladislav Vitalevich Markelov
IOIu. S. Osipov
Iu. S. Osipov
YAYu. A. Alekseeva
Yu. A. Alekseeva
SVS. V. Voloshin
S. V. Voloshin
NKN. A. Khasanova
N. A. Khasanova
AKAlexander Kulagin
Alexander Kulagin
BACKGROUND. In the Russian Federation, systematic evidence of treatment outcomes and prognosis evaluation in primary CNS lymphoma (PCNSL) patients is currently unavailable. AIM. To study the clinical and epidemiological characteristics as well as current medical practice and the first-line therapy outcomes in PCNSL patients. MATERIALS & METHODS. The study enrolled 127 adults with histologically verified PCNSL diagnosis treated from 2010 to 2024 at nine medical institutions in Saint Petersburg. Absolute majority (n = 119; 94 %) of them received various regimens of chemo- and/or immunochemotherapy (ICT). High-dose methotrexate (HD-МТХ) protocols were administered in 103 (87 %) cases, 86 % (n = 101) of PCNSL patients received rituximab. RESULTS. Response assessment was analyzed in 111 (87 %) patients. Objective response (OR) to the first-line therapy was 72 % (n = 80) including complete remissions in 38 (34 %) patients. With the follow-up of 12 months (range 0.4–151.1 months), the 2-year overall survival (OS) was 43 % (95 % confidence interval [95% CI] 34–54 %), and the 2-year event-free survival (EFS) was 30 % (95% CI 22–40 %). Prognostic factors included ECOG status and HD-МТХ administration. After ICT, 28 (38 %) patients with OR received radiation or high-dose therapy with autologous hematopoietic stem cell transplantation as consolidation treatment. Consolidation stage, irrespective of the chosen option, was associated with better rates of long-term survival: the 2-year OS was 78 % (95% CI 62–100 %), the 2-year EFS was 59 % (95% CI 41–84 %). CONCLUSION. The clinical profile of PCNSL patients, as revealed in this study, is generally consistent with published literature. Most patients received the treatment regimens in accordance with the international guidelines, however, in a part of them, suboptimal treatment was used. The best rates of long-term survival were reported in patients who achieved OR and subsequently received consolidation therapy.

6 July 2026 in Blood Immunology & Cellular Therapy
Verified
Journal Article
Open access
LFLiudmila Fedorova
Liudmila Fedorova
NMNatalia Mikhailova
Natalia Mikhailova
KLKirill V. Lepik
Kirill V. Lepik
VMVladislav Markelov
Vladislav Markelov
ACAndrey Chekalov
Andrey Chekalov
AKAlexander Kulagin
Alexander Kulagin